Menotrophin 75 IU Injection

Human Menopausal Gonadotrophin (HMG) | 75 IU FSH + 75 IU LH | Lyophilised Powder for Injection

Pharmaceutical-grade Menotrophin 75 IU Injection available to order online for USA and UK delivery. Prescription required. Used in IVF, ovulation induction, controlled ovarian stimulation, and male infertility treatment under specialist supervision.

Product Quick Facts

Order Menotrophin 75 IU Injection Online

Milan Medicals supplies pharmaceutical-grade Menotrophin 75 IU Injection for patients and clinics in the USA and UK. Each vial contains 75 IU FSH activity and 75 IU LH activity as a highly purified human menopausal gonadotrophin preparation, supplied with sterile diluent for reconstitution.

To order Menotrophin 75 IU Injection, a valid prescription from a licensed physician or reproductive medicine specialist is required. Upload your prescription at checkout or contact our pharmacy team for guidance on the ordering process.

Prescription Required. Menotrophin 75 IU Injection is a prescription-only medicine in the United States and the United Kingdom. Orders cannot be dispensed without a valid, verified prescription.

What is Menotrophin 75 IU Injection?

Menotrophin 75 IU Injection is a highly purified preparation of human menopausal gonadotrophin (HMG) containing 75 International Units of follicle-stimulating hormone (FSH) activity and 75 International Units of luteinising hormone (LH) activity per vial. It is extracted from the urine of postmenopausal women — in whom FSH and LH are naturally present in elevated concentrations — and undergoes multiple purification steps to produce a standardised, pharmaceutical-grade injectable product.

Menotrophin 75 IU is supplied as a lyophilised (freeze-dried) white powder in a glass vial, accompanied by a vial of sterile sodium chloride diluent for reconstitution immediately before injection. It is administered by subcutaneous or intramuscular injection under the direct supervision of a reproductive medicine specialist as part of a structured fertility treatment protocol.

Menotrophin has an established clinical history across multiple fertility indications — including IVF stimulation, ovulation induction, intrauterine insemination (IUI), polycystic ovarian disease (PCOD), and male hypogonadotropic hypogonadism — and is one of the most widely used gonadotrophin preparations in assisted reproductive technology worldwide.

Product Specifications

References

1. Medicines and Healthcare products Regulatory Agency (MHRA). Menopur 75 IU Summary of Product Characteristics. Electronic Medicines Compendium (EMC). medicines.org.uk.
2. U.S. Food and Drug Administration. Menopur (Menotropins for Injection) Prescribing Information. Ferring Pharmaceuticals Inc. FDA.gov.
3. British National Formulary (BNF). Menotrophin. Current Edition. London: BMJ Group and Pharmaceutical Press.
4. Lunenfeld B. Historical perspectives in gonadotrophin therapy. Human Reproduction Update. 2004;10(6):453–467.
5. American Society for Reproductive Medicine (ASRM). Gonadotropins for ovarian stimulation: a committee opinion. Fertility and Sterility. 2008.

How it works

Menotrophin works by supplying exogenous FSH and LH gonadotrophin activity to directly stimulate the reproductive organs in patients where endogenous pituitary hormonal output is insufficient to support normal follicular development or spermatogenesis.

FSH Activity — Follicular Development and Spermatogenesis

The FSH component of Menotrophin binds to receptors on ovarian granulosa cells in women, stimulating follicular recruitment, growth, and oestrogen production. In men, FSH acts on testicular Sertoli cells to support sperm maturation. FSH drives the early and mid-stages of folliculogenesis and is the primary hormone responsible for the multi-follicular development required in IVF stimulation protocols.

LH Activity — Steroidogenesis and Follicular Maturation

The LH component supports ovarian steroidogenesis and promotes the final stages of preovulatory follicular maturation in women. In men, LH stimulates Leydig cells in the testes to produce testosterone, which is essential for spermatogenesis. Menotrophin delivers FSH and LH in a 1:1 ratio, providing the combined gonadotrophin activity that mirrors the physiological hormonal environment required for normal reproductive function.

How Menotrophin Fits Into an IVF Protocol

In a typical IVF stimulation cycle, Menotrophin is administered daily from the early follicular phase as part of a controlled ovarian stimulation (COS) protocol. It is used alongside a GnRH agonist or antagonist to prevent premature ovulation. Follicular growth and oestradiol levels are monitored through regular ultrasound scans and blood tests. When follicles reach the appropriate size and maturity, a trigger injection of human chorionic gonadotrophin (hCG) is administered to complete oocyte maturation before egg retrieval.

IVF and Assisted Reproductive Technology (ART)

Menotrophin 75 IU is one of the most widely prescribed gonadotrophins in IVF and ART protocols worldwide. It stimulates the development of multiple ovarian follicles simultaneously, increasing the number of mature oocytes available for retrieval and fertilisation. Its combined FSH and LH activity makes it particularly suited to patients who may benefit from LH supplementation alongside FSH during controlled ovarian stimulation.

Ovulation Induction

Menotrophin is used to induce ovulation in women who are anovulatory — not producing eggs — due to insufficient pituitary gonadotrophin stimulation. This includes women with hypogonadotropic hypogonadism and women with polycystic ovarian disease (PCOD) who have not responded to clomiphene citrate. Ovulation is subsequently triggered by hCG administration when follicular monitoring confirms adequate maturity.

Intrauterine Insemination (IUI)

In IUI cycles, Menotrophin is used at lower stimulation doses to produce a controlled number of mature follicles — typically one to three — before ovulation is triggered and insemination performed. Careful monitoring is essential to reduce the risk of high-order multiple pregnancies.

Male Hypogonadotropic Hypogonadism and Low Sperm Count

In men with hypogonadotropic hypogonadism, where low sperm count or absent spermatogenesis is caused by insufficient pituitary gonadotrophin secretion rather than primary testicular failure, Menotrophin is used alongside hCG to stimulate sperm production. hCG is administered first to normalise testosterone levels, after which Menotrophin provides the FSH activity required to drive spermatogenesis. Treatment typically continues for a minimum of three to four months, with sperm count monitored throughout.

Dosage

Dosing of Menotrophin 75 IU Injection is highly individualised and must be determined exclusively by a qualified reproductive medicine specialist based on the clinical indication, patient age, baseline FSH levels, antral follicle count, body weight, and response to prior stimulation cycles if applicable. Typical starting doses in clinical practice range from 75 IU to 225 IU daily, with adjustments made based on follicular ultrasound monitoring and serum oestradiol measurements throughout the stimulation cycle. Maximum daily dose should not exceed 450 IU. Treatment duration varies by protocol — typically 8 to 14 days for IVF stimulation cycles. Do not self-adjust the dose without specialist guidance.

Reconstitution Instructions

Reconstitute the lyophilised powder with the sterile diluent vial provided immediately before administration. The reconstituted solution must be used immediately and any unused portion discarded. Do not use any diluent other than that supplied with the product unless directed by your prescribing physician.

Storage

Store at 2 to 25 degrees Celsius, protected from light. Do not freeze. Keep out of the reach of children. Do not use after the expiry date printed on the vial and outer carton. Dispose of used vials, needles, and syringes safely in accordance with local sharps disposal regulations.

Menotrophin 75 IU Injection carries a clinically significant safety profile. All patients must undergo a full medical evaluation by a qualified reproductive medicine specialist before starting treatment. The following information is for reference only. Always consult the full Summary of Product Characteristics (SmPC) and your prescribing physician.

Common Side Effects

Ovarian Hyperstimulation Syndrome (OHSS) — Important Warning

OHSS is the most clinically significant risk associated with Menotrophin therapy. Mild OHSS is relatively common and resolves without intervention. Severe OHSS is rare but potentially life-threatening. Symptoms of severe OHSS include pronounced abdominal swelling, severe pelvic pain, nausea, vomiting, difficulty breathing, decreased urination, and rapid weight gain due to fluid accumulation. Patients must discontinue treatment and seek immediate medical attention if severe OHSS symptoms develop. Risk is higher in patients with polycystic ovarian syndrome (PCOS) and in those with a high follicular response during stimulation.

Contraindications — Who Should Not Use Menotrophin

• Women who are pregnant or breastfeeding
• Women with primary ovarian failure (elevated baseline FSH indicating non-functioning ovaries)
• Uncontrolled thyroid, adrenal, or other non-gonadal endocrine disorders
• Hormone-sensitive tumours of the hypothalamus, pituitary, ovary, uterus, or breast
• Unexplained abnormal uterine bleeding
• Ovarian cysts or ovarian enlargement not attributable to polycystic ovarian disease
• Known hypersensitivity to menotrophin or any excipients in the formulation
• Men with primary testicular failure